title: Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study.
authors.forename: S Hossein
authors.initials: SH
authors.lastname: Fatemi
authors.forename: Mahtab K
authors.initials: MK
authors.lastname: Yousefi
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Kneeland
authors.forename: Stephanie B
authors.initials: SB
authors.lastname: Liesch
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Folsom
authors.forename: Paul D
authors.initials: PD
authors.lastname: Thuras
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D011810:Quinoxalines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012907:Smoking / Q000188:drug therapy; D000068580:Varenicline
chemical_list: D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline